Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10330376" target="_blank" >RIV/00064165:_____/16:10330376 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00091587 RIV/00216208:11110/16:10330376 RIV/65269705:_____/16:00066153

Výsledek na webu

<a href="http://dx.doi.org/10.1080/14737140.2016.1247699" target="_blank" >http://dx.doi.org/10.1080/14737140.2016.1247699</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/14737140.2016.1247699" target="_blank" >10.1080/14737140.2016.1247699</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management

Popis výsledku v původním jazyce

Introduction: Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pathomorphologically and immunohistochemically detectable lesion which biological significance and clinical relevance is unknown. Areas covered: We investigate methods of STIC diagnostics and we present an overview of recent studies and available knowledge on surgical management, adjuvant chemotherapy and subsequent follow-up procedure in women with an isolated STIC. Expert commentary: Patients found to have an incidental STIC lesion should be referred for screening of BRCA1/2 mutation. In absence of an invasive disease, follow-up of patient remains a reasonable choice. A rational scheme should include check-ups every 6 months consisting of gynecological examinations, CA 125 and/or HE4 and pelvic ultrasound examination by an expert sonographer.

Název v anglickém jazyce

Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management

Popis výsledku anglicky

Introduction: Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pathomorphologically and immunohistochemically detectable lesion which biological significance and clinical relevance is unknown. Areas covered: We investigate methods of STIC diagnostics and we present an overview of recent studies and available knowledge on surgical management, adjuvant chemotherapy and subsequent follow-up procedure in women with an isolated STIC. Expert commentary: Patients found to have an incidental STIC lesion should be referred for screening of BRCA1/2 mutation. In absence of an invasive disease, follow-up of patient remains a reasonable choice. A rational scheme should include check-ups every 6 months consisting of gynecological examinations, CA 125 and/or HE4 and pelvic ultrasound examination by an expert sonographer.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NV15-27695A" target="_blank" >NV15-27695A: Analýza genetické predispozice ke vzniku karcinomu ovaria pomocí Next Gene sekvenování</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Review of Anticancer Therapy

ISSN

1473-7140

e-ISSN

—

Svazek periodika

16

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

1311-1321

Kód UT WoS článku

000389183800011

EID výsledku v databázi Scopus

2-s2.0-84996644863